MwanzoMOLN • NASDAQ
add
Molecular Partners AG
Bei iliyotangulia
$ 3.56
Bei za siku
$ 3.58 - $ 3.80
Bei za mwaka
$ 3.36 - $ 12.70
Thamani ya kampuni katika soko
147.29M USD
Wastani wa hisa zilizouzwa
elfu 17.94
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 16.14M | 259.35% |
Mapato halisi | -16.77M | -48.09% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.45 | — |
EBITDA | -15.59M | -2.21% |
Asilimia ya kodi ya mapato | 0.01% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 130.91M | -24.82% |
Jumla ya mali | 141.10M | -23.98% |
Jumla ya dhima | 12.90M | -24.36% |
Jumla ya hisa | 128.19M | — |
hisa zilizosalia | 37.27M | — |
Uwiano wa bei na thamani | 1.03 | — |
Faida inayotokana na mali | -26.94% | — |
Faida inayotokana mtaji | -29.41% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -16.77M | -48.09% |
Pesa kutokana na shughuli | -17.08M | -0.18% |
Pesa kutokana na uwekezaji | 34.96M | 98.53% |
Pesa kutokana na ufadhili | elfu -302.00 | -0.67% |
Mabadiliko halisi ya pesa taslimu | 17.50M | 1,588.90% |
Mtiririko huru wa pesa | -13.72M | -22.38% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
159
